Effect of second-generation antipsychotics on cognition: current issues and future challenges

Generalized cognitive impairments are stable deficits linked to schizophrenia and key factors associated with functional disability in the disorder. Preclinical data suggest that second-generation antipsychotics could potentially reduce cognitive impairments; however, recent large clinical trials indicate only modest cognitive benefits relative to first-generation antipsychotics. This might reflect a limited drug effect in humans, a differential drug effect due to brain alterations associated with schizophrenia, or limited sensitivity of the neuropsychological tests for evaluating cognitive outcomes. New adjunctive procognitive drugs may be needed to achieve robust cognitive and functional improvement. Drug discovery may benefit from greater utilization of translational neurocognitive biomarkers to bridge preclinical and clinical proof-of-concept studies, to optimize assay sensitivity, enhance cost efficiency, and speed progress in drug development.

[1]  R. Emsley,et al.  The effects of sub-chronic clozapine and haloperidol administration on isolation rearing induced changes in frontal cortical N-methyl-d-aspartate and D1 receptor binding in rats , 2010, Neuroscience.

[2]  J. Sweeney,et al.  A comparison of neuropsychological dysfunction in first-episode psychosis patients with unipolar depression, bipolar disorder, and schizophrenia , 2009, Schizophrenia Research.

[3]  T. Nabeshima,et al.  Behavioral abnormality and pharmacologic response in social isolation-reared mice , 2009, Behavioural Brain Research.

[4]  J. Csernansky,et al.  Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy , 2009, BMC psychiatry.

[5]  R. Kahn,et al.  Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). , 2009, The American journal of psychiatry.

[6]  J. Sweeney,et al.  An fMRI study of visual attention and sensorimotor function before and after antipsychotic treatment in first-episode schizophrenia , 2009, Psychiatry Research: Neuroimaging.

[7]  J. Vázquez-Barquero,et al.  Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison. , 2009, The Journal of clinical psychiatry.

[8]  Philip D. Harvey,et al.  Abbreviated neuropsychological assessment in schizophrenia: Prediction of different aspects of outcome , 2009, Journal of clinical and experimental neuropsychology.

[9]  J. Sweeney,et al.  Pharmacological treatment effects on eye movement control , 2008, Brain and Cognition.

[10]  Sarah E. Forster,et al.  Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. , 2008, The American journal of psychiatry.

[11]  Ruben C. Gur,et al.  General and Specific Cognitive Deficits in Schizophrenia: Goliath Defeats David? , 2008, Biological Psychiatry.

[12]  T. McGlashan,et al.  Neuropsychological course in the prodrome and first episode of psychosis: Findings from the PRIME North America Double Blind Treatment Study , 2008, Schizophrenia Research.

[13]  D. Lewis,et al.  GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia. , 2008, Schizophrenia bulletin.

[14]  J. Gold,et al.  Initial phase 2 trial of a nicotinic agonist in schizophrenia. , 2008, The American journal of psychiatry.

[15]  Philip D. Harvey,et al.  Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS) , 2008, Schizophrenia Research.

[16]  Yuko Fujita,et al.  Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: Role of serotonin 5-HT1A receptors , 2008, European Neuropsychopharmacology.

[17]  John A. Sweeney,et al.  Reduced Attentional Engagement Contributes to Deficits in Prefrontal Inhibitory Control in Schizophrenia , 2008, Biological Psychiatry.

[18]  Koki Ito,et al.  Olanzapine and risperidone block a high dose of methamphetamine-induced schizophrenia-like behavioral abnormalities and accompanied apoptosis in the medial prefrontal cortex , 2008, Schizophrenia Research.

[19]  M. Yoshioka,et al.  Characterization of clozapine-induced changes in synaptic plasticity in the hippocampal–mPFC pathway of anesthetized rats , 2008, Brain Research.

[20]  J. Lieberman,et al.  Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia , 2008, Journal of the International Neuropsychological Society.

[21]  R. Rosenheck,et al.  Association of symptomatology and cognitive deficits to functional capacity in schizophrenia , 2008, Schizophrenia Research.

[22]  R. Roth,et al.  Clozapine Normalizes Prefrontal Cortex Dopamine Transmission in Monkeys Subchronically Exposed to Phencyclidine , 2008, Neuropsychopharmacology.

[23]  J. Sweeney,et al.  Oculomotor and neuropsychological effects of antipsychotic treatment for schizophrenia. , 2007, Schizophrenia bulletin.

[24]  Todd Lencz,et al.  Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? , 2007, Archives of general psychiatry.

[25]  P. Celada,et al.  Antipsychotic drugs reverse the disruption in prefrontal cortex function produced by NMDA receptor blockade with phencyclidine , 2007, Proceedings of the National Academy of Sciences.

[26]  J. Lieberman,et al.  Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. , 2007, The American journal of psychiatry.

[27]  Michael F. Green,et al.  Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. , 2007, Archives of general psychiatry.

[28]  A. Markou,et al.  Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats , 2007, Psychopharmacology.

[29]  Liang Li,et al.  Chronic administration of clozapine alleviates reversal-learning impairment in isolation-reared rats , 2007, Behavioural pharmacology.

[30]  J. Lieberman,et al.  Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. , 2007, The American journal of psychiatry.

[31]  N. Woodward,et al.  COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia , 2007, Schizophrenia Research.

[32]  D. Zald,et al.  A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: Dose effects and comparison to practice effects , 2007, Schizophrenia Research.

[33]  S. Killcross,et al.  Clozapine, SCH 23390 and α-flupenthixol but not haloperidol attenuate acute phencyclidine-induced disruption of conditional discrimination performance , 2007, Psychopharmacology.

[34]  Chunfu Wu,et al.  Differential effects of haloperidol, clozapine and olanzapine on learning and memory functions in mice , 2006, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[35]  C. Carter,et al.  Impairments in frontal cortical γ synchrony and cognitive control in schizophrenia , 2006, Proceedings of the National Academy of Sciences.

[36]  J. Hoch,et al.  The cost of schizophrenia: lessons from an international comparison. , 2006, Journal of Mental Health Policy and Economics.

[37]  J. Sweeney,et al.  Adverse effects of risperidone on spatial working memory in first-episode schizophrenia. , 2006, Archives of general psychiatry.

[38]  H. Küchenhoff,et al.  Neurocognitive functioning in patients with first-episode schizophrenia , 2006, European Archives of Psychiatry and Clinical Neuroscience.

[39]  David A Lewis,et al.  Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. , 2006, Archives of neurology.

[40]  C. Tamminga.  The neurobiology of cognition in schizophrenia. , 2006, The Journal of clinical psychiatry.

[41]  Jue He,et al.  The effects of chronic administration of quetiapine on the methamphetamine-induced recognition memory impairment and dopaminergic terminal deficit in rats , 2006, Behavioural Brain Research.

[42]  M. Geyer,et al.  Iloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats , 2006, Neuropharmacology.

[43]  M. Hajós.  Targeting information-processing deficit in schizophrenia: a novel approach to psychotherapeutic drug discovery. , 2006, Trends in pharmacological sciences.

[44]  R. Gur,et al.  A comparison of cognitive structure in schizophrenia patients and healthy controls using confirmatory factor analysis , 2006, Schizophrenia Research.

[45]  Jared X. Van Snellenberg,et al.  The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative review , 2006, Journal of psychopharmacology.

[46]  Haiyun Xu,et al.  The effects of chronic administration of quetiapine on the phencyclidine-induced reference memory impairment and decrease of Bcl-XL/Bax ratio in the posterior cingulate cortex in rats , 2006, Behavioural Brain Research.

[47]  M. Bardgett,et al.  The effects of clozapine on delayed spatial alternation deficits in rats with hippocampal damage , 2006, Neurobiology of Learning and Memory.

[48]  Jeffrey A. Lieberman,et al.  Long-Term Neurocognitive Effects of Olanzapine or Low-Dose Haloperidol in First-Episode Psychosis , 2006, Biological Psychiatry.

[49]  Matcheri S Keshavan,et al.  Longitudinal studies of antisaccades in antipsychotic-naive first-episode schizophrenia , 2006, Psychological Medicine.

[50]  Haiyun Xu,et al.  Quetiapine reverses the suppression of hippocampal neurogenesis caused by repeated restraint stress , 2005, Brain Research.

[51]  Philip D. Harvey,et al.  Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. , 2005, The American journal of psychiatry.

[52]  C. Nemeroff,et al.  Neurotensin-Deficient Mice Have Deficits in Prepulse Inhibition: Restoration by Clozapine but Not Haloperidol, Olanzapine, or Quetiapine , 2005, Journal of Pharmacology and Experimental Therapeutics.

[53]  J. Gold,et al.  Cognitive rehabilitation for schizophrenia and the putative role of motivation and expectancies. , 2005, Schizophrenia bulletin.

[54]  Herbert Y Meltzer,et al.  A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. , 2005, The international journal of neuropsychopharmacology.

[55]  M. Hummer,et al.  Patient outcomes in schizophrenia II: the impact of cognition , 2005, European Psychiatry.

[56]  Haiyun Xu,et al.  Olanzapine Attenuates the Okadaic Acid-Induced Spatial Memory Impairment and Hippocampal Cell Death in Rats , 2005, Neuropsychopharmacology.

[57]  J. Kew,et al.  Reversal of isolation-rearing-induced PPI deficits by an α7 nicotinic receptor agonist , 2005, Psychopharmacology.

[58]  D. Lewis,et al.  Cortical inhibitory neurons and schizophrenia , 2005, Nature Reviews Neuroscience.

[59]  D. Braff,et al.  Mismatch negativity deficits are associated with poor functioning in schizophrenia patients. , 2005, Archives of general psychiatry.

[60]  J. Sweeney,et al.  Abnormalities in visually guided saccades suggest corticofugal dysregulation in never-treated schizophrenia , 2005, Biological Psychiatry.

[61]  J. Callicott,et al.  Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. , 2004, The American journal of psychiatry.

[62]  W. Fleischhacker,et al.  Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. , 2004, The Journal of clinical psychiatry.

[63]  M. Thase,et al.  Neuropsychological dysfunction in antipsychotic-naive first-episode unipolar psychotic depression. , 2004, The American journal of psychiatry.

[64]  J. Lieberman,et al.  Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. , 2004, The American journal of psychiatry.

[65]  J. Sweeney,et al.  Pretreatment and longitudinal studies of neuropsychological deficits in antipsychotic-naı̈ve patients with schizophrenia , 2004, Schizophrenia Research.

[66]  Bita Moghaddam,et al.  Bringing Order to the Glutamate Chaos in Schizophrenia , 2003, Neuron.

[67]  J. Jentsch.  Pre-clinical models of cognitive dysfunction in schizophrenia: new avenues to addressing unmet needs , 2003, Clinical Neuroscience Research.

[68]  P. Jeffrey Conn,et al.  N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-d-aspartate receptor activity , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[69]  P. Corrigan,et al.  The effects of atypical antipsychotic medications on psychosocial outcomes , 2003, Schizophrenia Research.

[70]  Neil Woodward,et al.  Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol , 2003, Psychopharmacology.

[71]  B. Morris,et al.  Induction of Metabolic Hypofunction and Neurochemical Deficits after Chronic Intermittent Exposure to Phencyclidine: Differential Modulation by Antipsychotic Drugs , 2003, Neuropsychopharmacology.

[72]  G. Reynolds,et al.  The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat , 2003, Journal of psychopharmacology.

[73]  Michael F. Green,et al.  Impact of risperidone versus haloperidol on activities of daily living in the treatment of refractory schizophrenia. , 2002, Comprehensive psychiatry.

[74]  J. Gold,et al.  Another view of therapy for cognition in schizophrenia , 2002, Biological Psychiatry.

[75]  Michael F. Green,et al.  Recent studies on the neurocognitive effects of second-generation antipsychotic medications , 2002 .

[76]  Daniel R. Weinberger,et al.  Prefrontal neurons and the genetics of schizophrenia , 2001, Biological Psychiatry.

[77]  M. Strauss.  Demonstrating specific cognitive deficits: a psychometric perspective. , 2001, Journal of abnormal psychology.

[78]  R. Traub,et al.  Inhibition-based rhythms: experimental and mathematical observations on network dynamics. , 2000, International journal of psychophysiology : official journal of the International Organization of Psychophysiology.

[79]  Daniel R Weinberger,et al.  To Model a Psychiatric Disorder in Animals: Schizophrenia As a Reality Test , 2000, Neuropsychopharmacology.

[80]  E. Stip,et al.  Procedural learning in schizophrenia: further consideration on the deleterious effect of neuroleptics. , 2000, Brain and cognition.

[81]  D L Braff,et al.  Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications. , 2000, The American journal of psychiatry.

[82]  S. Kapur,et al.  Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. , 2000, The American journal of psychiatry.

[83]  P. Goldman-Rakic,et al.  Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. , 2000, Science.

[84]  A Labelle,et al.  Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. , 2000, Archives of general psychiatry.

[85]  B. Maher,et al.  Effects of clozapine on psychiatric symptoms, cognition, and functional outcome in schizophrenia. , 1999, The Journal of neuropsychiatry and clinical neurosciences.

[86]  L. DeLisi,et al.  Longitudinal neuropsychological follow-up study of patients with first-episode schizophrenia. , 1999, The American journal of psychiatry.

[87]  J. O'hanlon,et al.  Psychomotor, Cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic. , 1999, Journal of clinical psychopharmacology.

[88]  Norman Ringel,et al.  Social functioning and neurocognitive deficits in outpatients with schizophrenia: a 2-year follow-up 1 This work was presented in part at the Winter Workshop on Schizophrenia, Davos, Switzerland, 7–13 February 1998. 1 , 1999, Schizophrenia Research.

[89]  A. Malla,et al.  Symptoms and cognition as predictors of community functioning: a prospective analysis. , 1999, The American journal of psychiatry.

[90]  B. Moghaddam,et al.  Corticolimbic Dopamine Neurotransmission Is Temporally Dissociated from the Cognitive and Locomotor Effects of Phencyclidine , 1998, The Journal of Neuroscience.

[91]  S. Marder,et al.  Does risperidone improve verbal working memory in treatment-resistant schizophrenia? , 1997, The American journal of psychiatry.

[92]  Michael F. Green,et al.  What are the functional consequences of neurocognitive deficits in schizophrenia? , 1996, The American journal of psychiatry.

[93]  S. Sevy,et al.  The cost of cognitive impairment in schizophrenia , 1995, Schizophrenia Research.

[94]  P. Goldman-Rakic,et al.  Dopamine D2 receptor mechanisms contribute to age-related cognitive decline: the effects of quinpirole on memory and motor performance in monkeys , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[95]  R. Buchanan,et al.  The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance , 1994, Biological Psychiatry.

[96]  H. Meltzer,et al.  Effects of clozapine on cognitive function in schizophrenia. , 1994, The Journal of clinical psychiatry.

[97]  R. Gur,et al.  Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. , 1994, Archives of general psychiatry.

[98]  P. Goldman-Rakic,et al.  The role of D1-dopamine receptor in working memory: local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed-response task. , 1994, Journal of neurophysiology.

[99]  M. Strauss,et al.  Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. , 1989, Journal of abnormal psychology.

[100]  G Honigfeld,et al.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. , 1988, Archives of general psychiatry.

[101]  D. Perlick,et al.  Memory deficits and anticholinergic levels in chronic schizophrenia. , 1986, The American journal of psychiatry.

[102]  M. Strauss,et al.  Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients. , 1982, The American journal of psychiatry.

[103]  R. Casper,et al.  Antipsychotic Drugs: Clinical Pharmacology and Therapeutic Use , 1977, Drugs.

[104]  J. Sweeney,et al.  Effects of Risperidone on Procedural Learning in Antipsychotic-Naive First-Episode Schizophrenia , 2009, Neuropsychopharmacology.

[105]  D. Javitt,et al.  Neurophysiological biomarkers for drug development in schizophrenia , 2008, Nature Reviews Drug Discovery.

[106]  A. Awad,et al.  Impact of Atypical Antipsychotics on Quality of Life in Patients with Schizophrenia , 2004, CNS drugs.

[107]  H. Meltzer,et al.  The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. , 1999, Schizophrenia bulletin.

[108]  J. Lieberman,et al.  The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. , 1999, Schizophrenia bulletin.

[109]  R. Heinrichs,et al.  Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. , 1998, Neuropsychology.

[110]  J. Neale,et al.  The neuropsychological signature of schizophrenia: generalized or differential deficit? , 1994, The American journal of psychiatry.

[111]  J. Lieberman,et al.  Antipsychotic medication effects on neuropsychological functions. , 1992, Psychopharmacology bulletin.

[112]  P. Appelbaum,et al.  Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients. , 1990, Schizophrenia bulletin.

[113]  L. J. Chapman,et al.  The measurement of differential deficit. , 1978, Journal of psychiatric research.